a b s t r a c t TS-1 is an oral fluoropyrimidine anticancer drug that contains tegafur, gimeracil, and oteracil. A 78-yearold Japanese male who was diagnosed with carcinoma of the oral floor (rT4aN0M0) was prescribed a standard dose of TS-1 (80 mg/day). On Day 8 after administration of TS-1, an eruption developed. There was erythema, along with vesicles and erosions involving the lip, face, neck, trunk, limbs, and genitals. The drug-induced lymphocyte stimulation test (DLST) for TS-1 was negative on the 23 rd day, but positive on the 43 rd day (20 days after discontinuing prednisolone). The condition was diagnosed as StevenseJohnson syndrome due to TS-1 because of the clinical course and laboratory results. This case and 24 cases previously reported in the literature were analyzed. The types of drug eruption were drug-related lupus (9 cases), acral erythema (7 cases), scleroderma-like skin lesion (2 cases), StevenseJohnson syndrome (2 cases), lichenoid eruption (1 case), purpura (1 case), lichen planus (1 case), erythema multiforme (1 case), hypopigmentation (1 case) and toxic epidermal necrolysis (1 case), respectively. In view of the increasing usage of TS-1 in several common cancers, clinicians should be aware of drug eruptions due to TS-1. Copyright Ó 2013, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC. All rights reserved.
Introduction
TS-1 is an oral fluoropyrimidine anticancer drug that contains tegafur [a prodrug that cells metabolize to fluorouracil (FU)], gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades FU), and oteracil (which inhibits the phosphorylation of FU in the gastrointestinal tract, thus reducing its side effects on the gastrointestinal tract). 1 We describe the case of a patient who developed a rare complication of StevenseJohnson syndrome (SJS) 8 days after adjuvant TS-1 administration. To clarify the clinical characteristics of drug eruption associated with TS-1, this case and 24 previous cases reported in the literature were analyzed.
Case report
A 78-year-old Japanese man who was diagnosed with carcinoma of the oral floor (rT4aN0M0) was prescribed a standard dose of tegafur/ gimeracil/oteracil (TS-1) at 80 mg/day. On the Day 8 after TS-1 administration, he developed eruptions on his axillae. On the 10th day, TS-1 was discontinued because of worsening of the confluent erythema involving the body, blisters on his genitals, and erosions associated with left eye tearing. Therefore, he was treated with 30 mg of prednisolone (PSL). On the 15 th day, he developed fever. He also experienced diarrhea that could not be controlled with antidiarrheal medication. On the 18 th day, he was referred to our department.
On physical examination, erythema, vesicle formation, and erosions involving the lip, face, neck, trunk, limbs, and genitals were observed ( Figure 1 ). His laboratory investigation results on admission were as follows: white blood cell count, 1.246 Â 10 9 /L; absolute neutrophil count, 81.7%; eosinophil count, 0%; hemoglobin level, 110 g/L; and platelet count, 232 Â 10 9 /L. Levels of antinuclear antibody, ds-DNA, and anti-BP180 antibody were within normal ranges. Nikolsky's sign was negative. Ophthalmological evaluation did not reveal any eye involvement. A skin biopsy specimen taken from his right thigh showed slight hyperkeratosis, many necrotic keratinocytes in the epidermis, subepidermal bulla formation, and vacuolar degeneration of the basal layer with infiltrations mainly comprising lymphocytes and eosinophils. In addition, lymphocytes and eosinophils had infiltrated the vessels of the superficial dermis ( Figure 2 ).
On the 23 rd day, the eruption was improved and therefore we discontinued oral PSL. The drug-induced lymphocyte stimulation test (DLST) performed at that point was negative for TS-1 (stimulation index, 162%). On the 43 rd day (20 days after discontinuing PSL), the results of closed patch tests performed using 50%, 25%, and 12.5% TS-1 on the lesional area were negative, but the DLST result * Corresponding author. 5 Zaifu-cho, Hirosaki 036-8562, Japan. Tel.: þ81 172 39 5087; fax: þ81 172 37 6060.
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Dermatologica Sinica was positive (stimulation index, 366%). We diagnosed the condition as TS-1-associated. SJS was diagnosed on the basis of the clinical course and laboratory results.
Discussion
A total of 25 cases involving TS-1-associated drug eruptions were analyzed 1e5 ( Table 1) . Levels of antinuclear antibody were positive in Cases 1 and 23. The results of patch tests were negative in Cases 2, 11, 13, 17, and our case. The DLST results were positive in Case 2 and our case, but the results were negative in Cases 13, 15, and 17. The results of drug challenge test were positive in Cases 1, 4, 9, 11, and 12.
In patients who are suspected to develop allergic reactions, DLST involving the incorporation of [ 3 H]thymidine ratio into the DNA of lymphocytes derived from patients, is generally employed for identifying drugs that could induce allergy. However, DLST results may show a false-negative response because of steroid, antitumor, and immunosuppressive drugs. Immediately after the onset of drug allergies, patients are also thought to be more susceptible to false-negative reactions. In view of the occurrence of false-negative results, the possibility of drug-induced allergy in patients receiving TS-1 should be carefully evaluated using a combination of other clinical examinations.
Common features of drug-related lupus are as follows: rare cutaneous manifestations, a high incidence of antihistone antibodies, and reversible symptoms after withdrawal of offending agents. 6 The frequency of discoid lupus erythematosus-like eruption is about 10% among all cases of drug eruptions induced by FU, based on the statistical report of Fukuda, 3 but the finding is the proportion of drug-related lupus (9 of 24; 37.5%) in this study. Basal cells are the target cells most affected by FU agents, because they are stem cells and are multipotent. Therefore, basal cells damaged by FU agents seem to be highly susceptible to ultraviolet light (UVL) irradiation, which induces liquefaction changes and patchy lymphocytic infiltrations. 6 Drug-related lupus by FU agent may be an excellent model for understanding the pathomechanisms of development of discoid lesions. 6 Bleomycin and cisplatin are known to induce systemic sclerosislike reactions in a genetically susceptible host. 7 Similarly, toxic effects or immune system modulation by the FU might be responsible for systemic sclerosis-like reactions.
FU exerts its antitumor effects through several mechanisms, including inhibition of RNA synthesis and function, inhibition of thymidylate synthase activity, and incorporation into DNA, leading to DNA strand breaks. 8 When FU is orally administered, extensive first-pass metabolism of FU in the gastrointestinal wall and liver decreases FU plasma levels and causes severe intestinal mucosal damage. 8 The potent inhibition of dihydropyrimidine dehydrogenase by gimeracil present in TS-1 may expose the patient to a high level of active FU metabolite. This may induce a high incidence of drug eruption.
To the best of our knowledge, this is the first review of the literature associated with TS-1. In view of the increasing usage of TS-1 in several common cancers, clinicians should be aware of drug eruptions associated with TS-1 administration.
